Share on LinkedInShare on LinkedIn

ARTICLE · 06 DECEMBER 2018

Supreme Court Of Canada Leave Applications - November 2018

Supreme Court of Canada denies Eli Lilly leave to appeal in olanzapine section 8 damages action.

CanadaIntellectual Property

Supreme Court of Canada denies Eli Lilly leave to appeal in olanzapine section 8 damages action. On November 8, 2018, Eli Lilly was denied leave to appeal (docket No. 38077) the Federal Court of Appeal (FCA)'s decision (reported here) which affirmed the trial decision awarding more than $70 million to Teva under section 8 of the Patented Medicines (Notice of Compliance) Regulations in respect of olanzapine (Eli Lilly's ZYPREXA). The FCA granted Teva's cross-appeal seeking to add to its recovery lost pipefill sales and an adjustment to account for an under-reporting of sales in the data relied on by both parties' experts.

Supreme Court of Canada denies Teva leave to appeal in levofloxacin damages assessment. On November 8, 2018, Teva was denied leave to appeal (docket No. 38033) the FCA's decision (reported here) which affirmed the trial judge's quantification of damages (close to $19 million) from infringement of Janssen's patent for levofloxacin (LEVAQUIN). The

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from